E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Secondary Hyperparathyroidism (sHPT) Receiving Maintenance Haemodialysis |
|
E.1.1.1 | Medical condition in easily understood language |
Secondary Hyperparathyroidism (sHPT) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Hormonal diseases [C19] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10020708 |
E.1.2 | Term | Hyperparathyroidism secondary |
E.1.2 | System Organ Class | 10014698 - Endocrine disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of etelcalcetide in reducing the intact parathyroid hormone (iPTH) level in children ages ≥ 2 to < 18 years with secondary hyperparathyroidism (SHPT) receiving maintenance hemodialysis. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the efficacy of etelcalcetide in reducing the iPTH level by > 30%. To characterize change in laboratory markers of chronic kidney disease (CKD) following etelcalcetide treatment. To characterize the safety of etelcalcetide treatment based on laboratory values. To characterize the pharmacokinetic (PK) of etelcalcetide treatment after single and multiple doses. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
101. Subject’s legally acceptable representative has provided informed consent when the subject is legally too young to provide informed consent and the subject has provided written assent based on local regulations and/or guidelines prior to any study-specific activities/procedures being initiated. 102. Male or female subjects ≥ 2 to < 18 years of age at the time of enrollment. 103. Targeted dry weight ≥ 7 kg at the time of screening Week -1. 104. Diagnosed with CKD and SHPT undergoing hemodialysis/hemodiafiltration TIW at the time of screening ≥1 month. 105. Diagnosis of SHPT with the mean of the 2 consecutive central laboratory iPTH values > 300 pg/mL during screening, on separate days and within 2 weeks of enrollment obtained from the central laboratory during screening . 106. Serum cCa value ≥ 9.0 mg/dL (2.25 mmol/L) obtained from the central laboratory during screening. 107. Dialysate Ca level ≥ 2.5 mEq/L for at least 1 month prior to screening and throughout the duration of the study. 108. Subject receiving active vitamin D sterols must have had no more than a maximum dose change of 50% within the 2 weeks prior to screening laboratory assessments, remain stable through enrollment, and be expected to maintain stable doses for the duration of the study, except for adjustments allowed per protocol. 109. Subject receiving phosphate binders must have had no more than a maximum dose change of 50% within the 2 weeks prior to screening laboratory assessments, remain stable through enrollment, and be expected to maintain stable dose for the duration of the study, except for adjustments allowed per protocol. 110. Subject receiving Ca supplements must have had no more than a maximum dose change of 50% within the 2 weeks prior to screening laboratory assessments, remain stable through enrollment, and be expected to maintain stable dose for the duration of the study, except for adjustments allowed per protocol. 111. SHPT not due to vitamin D deficiency, per investigator assessment. |
|
E.4 | Principal exclusion criteria |
201 History of congenital long QT syndrome, 2nd or 3rd degree heart block, ventricular tachyarrhythmia’s, history of symptomatic ventricular dysrhythmias Torsades de Pointes or other conditions associated with prolonged QT interval 202 Anticipated or scheduled parathyroidectomy during the study period 203 Anticipated or scheduled kidney transplant during the study period 204 Subject has received a parathyroidectomy within 6 months prior to enrollment 205 Current malignancy or history of other malignancy, except non-melanoma skin cancers within the last 5 years Prior/Concomitant Therapy 206 Use of concomitant medications that may prolong the QTc (eg, ondansetron, albuterol, sotalol, amiodarone, erythromycin, or clarithromycin). 207 Receipt of cinacalcet therapy within 30 days prior screening and through enrollment 208 Receipt of etelcalcetide therapy within 6 months prior screening and through enrollment 209 All herbal medicines (eg, St. John’s wort), vitamins, and supplements consumed by the subject within the 30 days prior to enrollment, and continuing use if applicable, will be reviewed by the Principal Investigator and the Amgen Medical Monitor. Written documentation of the review and Amgen acknowledgment is required for subject participation 210 Use of any over-the-counter or prescription medications within the 14 days or 5 half-lives (whichever is longer) prior to enrollment that are not established therapies for subjects with renal disease or other conditions secondary to renal disease will be reviewed by the Principal Investigator and the Amgen Medical Monitor. Written documentation of the review and Amgen acknowledgment is required for subject participation. Paracetamol for analgesia will be allowed Prior/Concurrent Clinical Study Experience 211 Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded 212 Subject has significant abnormalities on the most recent central laboratory test during the screening period prior to enrollment per the Investigator including but not limited to the following: a. Serum transaminase (alanine aminotransferase [ALT] or serum glutamic pyruvic transaminase [SGPT], aspartate aminotransferase [AST], or serum glutamic oxaloacetic transaminase [SGOT]) > 1.5 times the upper limit of normal (ULN) 213 Corrected QT interval > 500 ms, using Bazett’s formula 214 Corrected QT interval ≥ 450 to ≤ 500 ms, using Bazett’s formula, unless written permission to enroll is provided by the investigator after consultation with a pediatric cardiologist 215 Subject has a clinically significant electrocardiogram (ECG) abnormality (eg, unstable arrhythmia) during screening that, in the opinion of the investigator, could pose a risk to subject safety or interfere with the study evaluation 216 New onset or worsening of a pre-existing seizure disorder 217 Subjects on anti-convulsant medication must be on a stable and therapeutic dose for 3 months prior to screening (if blood level monitoring is clinically available, then the subject must have a therapeutic blood level within 1 week of enrollment) 218 Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 3 months after the last dose of etelcalcetide. (Females of childbearing potential should only be included in the study after a confirmed menstrual period and a negative highly sensitive serum pregnancy test within 7 days prior to the first dose of investigational product) 219 Female subjects of childbearing potential unwilling to use 1 highly effective or acceptable method of effective contraception during treatment and for an additional 3 months after the last dose of investigational product 220 Female subjects of childbearing potential with a positive pregnancy test assessed at screening by a serum pregnancy test 221 Subject has known sensitivity to etelcalcetide or excipients to be administered during dosing 222 Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge 223 History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) or unacceptable physical findings, that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion 224 Subject previously has entered this study or previously received treatment with etelcalcetide 225 Anemia, which in the opinion of the investigator makes it not advisable to undergo sequential blood draws 226 History of unstable chronic heart failure within the last 1 year prior to screening |
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Percent change in iPTH from baseline during the efficacy assessment period (EAP) at weeks 20 to 26. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Day 1, Week 20, 21, 22, 23, 24, 25 and 26. |
|
E.5.2 | Secondary end point(s) |
• Achievement of a > 30% reduction from baseline in mean iPTH during the EAP. • Percent change from baseline in corrected total serum calcium (Ca) and serum phosphorus from baseline during the EAP. • Occurrence of corrected serum Ca levels < 8.0 mg/dL (2.0 mmol/L) any time during the study. • Changes in laboratory parameters, including clinical chemistry. • Occurrence of hypocalcemia (corrected serum Ca levels < 8.4 mg/dL). • Etelcalcetide plasma concentrations before and at the end of dialysis after single and multiple doses. • Etelcalcetide PK parameters including, but not limited to, maximum plasma concentration (Cmax) and plasma trough concentrations (Cmin). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
•Day 1, Week 20, 21, 22, 23, 24, 25 and 26 •Day 1, Week 20, 21, 22, 23, 24, 25 and 26 •Weekly throughout study •Day 1 (pre-dialysis/post-dialysis), Week 5 (pre-dialysis/post-dialysis), Week 9 (pre-dialysis/post-dialysis), Week 13 (pre-dialysis/post-dialysis), Week 17 (pre-dialysis/post-dialysis), Week 21 (pre-dialysis/post-dialysis), Week 27 (pre-dialysis), End of Study (pre-dialysis).
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 27 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 11 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 11 |